THYROLAR-1
LOE ApproachingNDAORALTABLET
Approved
Nov 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THYROLAR-1 is an oral tablet approved in 1969 for thyroid hormone replacement therapy. The specific mechanism of action and pharmacologic class are not disclosed in available data. This product treats patients requiring thyroid hormone supplementation.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting reduced team investment and potential restructuring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and LOE approaching, career opportunities on THYROLAR-1 are limited and centered on defensive commercial strategies. Professionals should view this assignment as a platform for portfolio management expertise and cost-optimization skills rather than growth-driven brand building.
Brand Manager (legacy products)Field Sales
Worked on THYROLAR-1 at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.